ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Basic Study |
Article Title |
Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Min-Wei Yang, Xue-Liang Fu, Yong-Sheng Jiang, Xiao-Jing Chen, Ling-Ye Tao, Jian-Yu Yang, Yan-Miao Huo, Wei Liu, Jun-Feng Zhang, Pei-Feng Liu, Qiang Liu, Rong Hua, Zhi-Gang Zhang, Yong-Wei Sun and De-Jun Liu |
ORCID |
|
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Municipal Commission of Health and Family Planning of Shanghai |
20174Y0243 |
Cultivating Funds of Renji Hospital, School of Medicine, Shanghai Jiaotong University |
PYXJS 16-002 |
Municipal Commission of Health and Family Planning of Shanghai |
20154Y0163 |
|
Corresponding Author |
De-Jun Liu, MAMS, Doctor, Doctor, Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, No 160 Pu Jian Road, Shanghai 200127, China. liudj1126@yeah.net |
Key Words |
Programmed death 1; Programmed death ligand 1; Gastric neuroendocrine carcinomas; Prognosis; Tumor infiltrating lymphocytes |
Core Tip |
This study for the first time demonstrated that programmed death ligand 1 (PD-L1) can be expressed by gastric neuroendocrine carcinomas (G-NECs) cancer cells and the high PD-L1 expression was associated with poor prognosis. And the high expression of PD-L1 may due to the copy number variant of PD-L1 gene or stimulation of tumor infiltrating lymphocytes. These findings provided important implications for the potential use of antibody therapies targeting the PD-1/PD-L1 signaling pathway in G-NECs. |
Publish Date |
2019-04-13 06:00 |
Citation |
Yang MW, Fu XL, Jiang YS, Chen XJ, Tao LY, Yang JY, Huo YM, Liu W, Zhang JF, Liu PF, Liu Q, Hua R, Zhang ZG, Sun YW, Liu DJ. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. World J Gastroenterol 2019; 25(14): 1684-1696 |
URL |
https://www.wjgnet.com/1007-9327/full/v25/i14/1684.htm |
DOI |
https://dx.doi.org/10.3748/wjg.v25.i14.1684 |